Sector consensus Celltrion, Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 10/09/2024			5-day change	1st Jan Change
195,800.00 ^KRW	+1.93%		-0.66%	-2.83%

08-29	Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	CI
08-26	European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	CI

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	4m Target Price Revision	Average Target P.	Ecart obj. / dr	Nbr of analysts
CELLTRION, INC.		246,777.78	+28.46%	18
LONZA GROUP AG		623.67	+14.81%	21
IQVIA HOLDINGS INC.		276.53	+14.81%	21
ALNYLAM PHARMACEUTICALS, INC.		283.17	+11.85%	27
MODERNA, INC.		125.71	+64.10%	21
ICON PUBLIC LIMITED COMPANY		365.40	+22.33%	15
UNITED THERAPEUTICS CORPORATION		350.71	+0.57%	13
BIO-TECHNE CORPORATION		82.55	+14.52%	13
MEDPACE HOLDINGS, INC.		406.91	+19.90%	9
QIAGEN N.V.		50.97	+11.08%	17
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.		224.07	+19.09%	17
TEMPUS AI, INC	-	46.00	-2.69%	8
IONIS PHARMACEUTICALS, INC.		62.91	+30.17%	25
REVOLUTION MEDICINES, INC.		59.21	+40.58%	14
BACHEM HOLDING AG		82.83	+8.00%	6
HANGZHOU TIGERMED CONSULTING CO., LTD		69.82	+41.92%	16
BLUEPRINT MEDICINES CORPORATION		127.35	+47.14%	17
IMMUNOVANT, INC.		48.43	+54.03%	14
PHARMARON BEIJING CO., LTD.		22.63	+12.26%	12
Average		13,162.46	+23.84%	16
Weighted average by Cap.		23,588.65	+22.47%	18